Boehringer Ingelheim is poised for major milestones pending FDA regulatory decisions on two late-stage candidates: zongertinib, a HER2-selective tyrosine kinase inhibitor targeting advanced non-small cell lung cancer, and nerandomilast, a PDE4B inhibitor for idiopathic pulmonary fibrosis (IPF). Zongertinib demonstrated a 71% objective response rate in heavily pretreated patients and may become the first oral HER2-targeted therapy in this indication. Nerandomilast’s Phase 3 data suggest improved outcomes over current standards but not revolutionary changes. The company highlights the large patient populations affected and expresses hope for meaningful therapeutic advances. Additional pipeline candidate verducatib, a DPP1/CatC inhibitor, is also in late-stage study for bronchiectasis.